BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioSyent Pharma Inc. Signs License and Distribution Agreement With Notlers


1/22/2010 8:46:01 AM

MISSISSAUGA, ONTARIO--(Marketwire - January 22, 2010) - BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) announces that its subsidiary BioSyent Pharma Inc. has signed a license and distribution agreement with Notlers for Virsani™ personal sanitizer. The agreement grants BioSyent Pharma the exclusive rights to manufacture, market, and distribute Virsani™ in Canada and the United States. Virsani™ kills viruses, bacteria, and other pathogens on hands and surfaces and is available in a convenient aerosol can that is small enough to fit in a small purse, pocket or desk drawer making it ideal for mobile personal hygiene. Virsani™ can disinfect both hands and personal spaces like computer keyboards, telephones, common work areas, and surfaces in fitness clubs and public washrooms.

Virsani™ has been approved by Health Canada and is currently available in over 1,200 retail locations including certain Rexall PharmaPlus, Pharmasave, International News, 7-Eleven, and Mac's Convenience stores.

"Consumer awareness of the importance of personal hygiene has been greatly increased over the last several years as a result of outbreaks such as H1N1 flu virus, Bird Flu, and SARS", said Rene Goehrum, CEO of BioSyent. "Virsani is a unique, convenient product that consumers can use at home, the workplace, in public places and when they are travelling, to provide safe and effective sanitization when they encounter such viruses and bacteria".

BioSyent's sales and marketing activity on Virsani™ will commence immediately.

BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. These pharmaceuticals will compete in both the branded and generic market segments and will not require further product development investment other than regulatory costs.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.


Contacts:
BioSyent Inc.
Rene C. Goehrum
President and CEO
(905) 206-0013
(905) 206-1413 (FAX)
www.biosyent.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES